Verve Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Verve Therapeutics, Inc. carries a market capitalization of 994.04M, placing it among publicly traded companies globally. Its enterprise value stands at -34.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 994.04M |
| Enterprise Value | -34.82M |
Share Statistics
Verve Therapeutics, Inc. currently has 89.14M shares outstanding.
| Shares Outstanding | 89.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.60, and the price-to-book ratio stands at -0.51.
| PE Ratio | N/A |
| PS Ratio | 6.60 |
| PB Ratio | -0.51 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | -2.85 |
| P/OCF Ratio | -2.76 |
Enterprise Valuation
| EV / Sales | 1.10 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Verve Therapeutics, Inc. maintains a current ratio of 9.84, meaning it holds 9.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.84 |
| Quick Ratio | 9.59 |
| Debt / Equity | 14.50 |
| Debt / EBITDA | -0.34 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -26.89 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 322,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Verve Therapeutics, Inc.'s stock has gained approximately 117.80822% over the past 52 weeks. The 50-day moving average sits at 8.21, while the 200-day moving average is 6.45.
| Beta (5Y) | N/A |
| 52-Week Price Change | 117.80822% |
| 50-Day Moving Average | 8.21 |
| 200-Day Moving Average | 6.45 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Verve Therapeutics, Inc. generated 59.61M in revenue and converted that into -181.01M in net income, yielding earnings per share of -2.10. EBITDA reached -201.61M, while operating income came in at -208.45M.
| Revenue | 59.61M |
| Gross Profit | N/A |
| Operating Income | -208.45M |
| Pretax Income | -180.68M |
| Net Income | -181.01M |
| EBITDA | -201.61M |
| EBIT | -208.45M |
| Earnings Per Share (EPS) | -2.10 |
Balance Sheet
Verve Therapeutics, Inc. holds 497.08M in cash and equivalents against 68.64M in total debt, resulting in a net debt position of -96.55M. Total book value stands at -773.96M, with working capital of 459.67M providing operational flexibility.
| Cash & Cash Equivalents | 497.08M |
| Total Debt | 68.64M |
| Net Debt | -96.55M |
| Equity (Book Value) | -773.96M |
| Book Value Per Share | -8.99 |
| Working Capital | 459.67M |
Cash Flow
Verve Therapeutics, Inc. produced -142.45M in operating cash flow over the past twelve months. After subtracting -4.53M in capital expenditures, free cash flow totaled -146.98M - equivalent to -1.71 per share.
| Operating Cash Flow | -142.45M |
| Capital Expenditures | -4.53M |
| Free Cash Flow | -146.98M |
| FCF Per Share | -1.71 |
Margins
Verve Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -349.68 and net profit margin of -303.64 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -349.68 |
| Pretax Margin | -303.09 |
| Profit Margin | -303.64 |
| EBITDA Margin | -338.21 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.72 |
| FCF Yield | -35.04 |
Scores
Verve Therapeutics, Inc. posts an Altman Z-Score of -0.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.21 |